| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C3c |
| Uniprot No | P01024 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 672-747aa |
| 氨基酸序列 | SVQLTEKRMDKVGKYPKELRKCCEDGMRENPMRFSCQRRTRFISLGEACK KVFLDCCNYITELRRQHARASHLGLA |
| 预测分子量 | 9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于C3c重组蛋白的参考文献(基于公开文献模拟，非真实引用)：
---
1. **文献名称**：*Recombinant expression and functional characterization of human complement C3c in inflammatory disease models*
**作者**：Smith A, et al.
**摘要**：本研究成功在大肠杆菌中表达并纯化重组人C3c蛋白，验证其与补体受体CR2的结合活性，并证明其在类风湿性关节炎小鼠模型中可抑制炎症反应。
---
2. **文献名称**：*Structural insights into C3c protein dynamics by cryo-EM: Implications for complement regulation*
**作者**：Li H, et al.
**摘要**：通过冷冻电镜解析重组C3c的高分辨率结构，揭示其构象变化如何影响补体旁路途径的调控机制，为靶向补体系统的药物设计提供结构基础。
---
3. **文献名称**：*Optimized production of recombinant C3c in mammalian cells for therapeutic antibody screening*
**作者**：Wang Y, et al.
**摘要**：开发了基于HEK293细胞的重组C3c高效表达系统，用于高通量筛选抑制补体过度激活的单克隆抗体，在体外实验中发现两种候选抗体可显著降低补体介导的细胞损伤。
---
**备注**：若需具体文献，建议通过PubMed或Web of Science搜索关键词“recombinant C3c protein”或“C3c complement fragment”获取最新研究。实际研究中可能存在更多关于C3c重组表达及功能的文献。
C3c recombinant protein is a engineered form of the C3c fragment derived from complement component C3. a central player in the complement system—an essential part of innate immunity. The complement system enhances pathogen clearance, inflammation, and immune complex regulation. C3. as the most abundant complement protein, undergoes proteolytic cleavage during activation: C3 is split into C3a (anaphylatoxin) and C3b, which opsonizes pathogens. Further degradation of C3b by Factor I and cofactors generates C3c and C3dg. C3c retains multiple functional domains of the parent C3 molecule, including the α-chain regions involved in interactions with complement regulators and receptors.
Recombinant C3c is produced using biotechnological methods (e.g., bacterial or mammalian expression systems) to enable controlled studies of complement pathways. Its production typically involves cloning the C3c-coding sequence into expression vectors, followed by purification via affinity chromatography. This recombinant form preserves structural and functional characteristics, allowing researchers to investigate its role in immune modulation without interference from other complement components.
C3c is implicated in regulating inflammatory responses and immune complex processing. It interacts with complement receptors (e.g., CR1) and inhibitors (e.g., Factor H), influencing downstream effector functions. Studies highlight its relevance in diseases like autoimmune disorders (e.g., lupus) and age-related macular degeneration, where dysregulated complement activity drives pathology. Recombinant C3c serves as a vital tool for dissecting complement activation mechanisms, developing diagnostic assays, and screening therapeutic agents targeting complement overactivation. Its stability and defined composition make it preferable over native C3c isolated from serum, which may contain contaminants. Ongoing research explores its potential as a biomarker or therapeutic target in complement-mediated conditions.
×
